key: cord-1035347-dcfzpjp9
authors: O’Hare, Michael; Amarnani, Dhanesh; Whitmore, Hannah A.B.; An, Miranda; Marino, Claudia; Ramos, Leslie; Delgado-Tirado, Santiago; Hu, Xinyao; Chmielewska, Natalia; Chandrahas, Anita; Fitzek, Antonia; Heinrich, Fabian; Steurer, Stefan; Ondruschka, Benjamin; Glatzel, Markus; Krasemann, Susanne; Sepulveda-Falla, Diego; Lagares, David; Pedron, Julien; Bushweller, John H.; Liu, Paul; Arboleda-Velasquez, Joseph F.; Kim, Leo A.
title: Targeting RUNX1 prevents pulmonary fibrosis and reduces expression of SARS-CoV-2 host mediators
date: 2021-04-21
journal: Am J Pathol
DOI: 10.1016/j.ajpath.2021.04.006
sha: ef5736248f0832d4dfe3d72dbb9deaa4aae289e1
doc_id: 1035347
cord_uid: dcfzpjp9

Pulmonary fibrosis (PF) can arise from unknown causes as in idiopathic pulmonary fibrosis (IPF), or as a consequence of infections including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Current treatments for PF slow, but do not stop disease progression. We report that treatment with a RUNX1 inhibitor (Ro24-7429), previously found to be safe, though ineffective, as a Tat inhibitor in patients with HIV, robustly ameliorates lung fibrosis and inflammation in the bleomycin-induced PF mouse model. RUNX1 inhibition blunted fundamental mechanisms downstream pathological mediators of fibrosis and inflammation including TGF-β1 and TNF-α in cultured lung epithelial cells, fibroblasts, and vascular endothelial cells indicating pleiotropic effects. RUNX1 inhibition also reduced the expression of ACE2 and FURIN, host proteins critical for SARS-CoV-2 infection, in mice and in vitro. A subset of human lungs with SARS-CoV-2 infection overexpress RUNX1. These data suggest that RUNX1 inhibition via repurposing of Ro24-7429 may be beneficial for PF and to battle SARS-CoV-2, by reducing expression of viral mediators and by preventing respiratory complications.

that treatment with a RUNX1 inhibitor (Ro24-7429), previously found to be safe, though 68 ineffective, as a Tat (1-3) . The cause of pulmonary 88 fibrosis is unknown in most cases, so is termed idiopathic pulmonary fibrosis (IPF). IPF is 89 estimated to affect approximately 50 in 100,000 individuals, making IPF the most common 90 interstitial lung disease in the US with a median survival of 3-5 years after diagnosis (4, 5) . 91 Despite recent developments in anti-fibrotic drugs such as nintedanib and pirfenidone, which 92 slow IPF progression, there is still no widely accepted treatment that can reduce mortality in IPF 93 (6). There is a dire need to identify therapeutics that modulate key targets in the pathological 94 mechanisms of lung fibrosis. The repurposing of existing therapeutics with strong safety profiles 95 may provide an accelerated path to identifying much-needed treatments as the incidence of IPF is 96 rising (7, 8) . It is known that the risk factors for idiopathic pulmonary fibrosis (IPF) are also risk 97 factors shared with patients infected with SARS CoV-2, suggesting the possibility that patients 98 with IPF may be at increased risk of severe COVID-19 and associated with an increased 99 mortality (9). Additionally, the recent SARS-CoV-2 pandemic has the potential to cause a surge 100 of post viral-infection induced cases of PF worldwide (10-13). 101 Critical pathophysiological mechanisms involved in lung pathology associated with SARS-CoV-suggest that up to 40% of hospitalized patients with COVID-19 develop acute respiratory 109 distress syndrome (ARDS) and approximately 30% of these cases develop fibrotic changes (18, 110 19). Although remdesivir, dexamethasone, and anti-SARS-CoV-2 antibody cocktails have 111 received emergency approvals for the treatment of COVID-19, there is a critical clinical need for 112 new therapies that can be easily administered and significantly impact clinical outcomes (20) (21) (22) . 113 RUNX1 is a transcription factor critical for the process of regulating the differentiation of 114 hematopoietic stem cells during development (23). RUNX1 functions as the α-DNA-binding 115 component of the transcription factor core-binding factor (CBF) in association with CBFβ (24) . 116 While RUNX1 is recurrently mutated in sporadic myelodysplastic syndrome and leukemia, 117 CBFβ mutations are found in 10-15% of adult de novo acute myeloid leukemia (AML) cases. 118 These links to cancer have generated interest in the discovery and characterization of small 119 molecule modulators of RUNX1 function, though to date none have been approved for clinical 120 use (25, 26) . RUNX1 functions in TNF-α-driven proliferation and migration of vascular 121 endothelial cells, driving aberrant angiogenesis in a VEGF-independent pathway (27, 28) . 122 RUNX1 also functions as a master regulator of epithelial to mesenchymal transition (EMT) via 123 TGF-2 signaling, suppressing epithelial phenotypes and promoting mesenchymal 124 transformation in a blinding condition associated with ocular fibrosis called proliferative 125 vitreoretinopathy (29). These results suggest that RUNX1 activity is associated with both 126 pathological angiogenesis and fibrosis key cellular processes found in response to SARS- from Millipore-Sigma (Burlington, MA, USA). We contracted the synthesis of Ro24-7429 as 152 fee-for-service from MedKoo Biosciences, which confirmed the correct structure by 1H-NMR 153 J o u r n a l P r e -p r o o f nuclear magnetic resonance (NMR) and mass spectrometry, and purity >99% by high-154 performance liquid chromatography (HPLC, data not shown). The remaining Ro24-7429 was 155 received as a kind gift from Paul Liu. The CBFβ-RUNX1 protein-protein interaction inhibitor, 156 AI-14-91 was synthesized as described previously (19) and was received as a kind gift from the 157 Bushweller Lab. (Table 1) Fig. S1 ).

We evaluated the expression of RUNX1 and known markers of fibrosis in lung tissue of mice 329 instilled with bleomycin treated with Ro24-7429 or vehicle. As expected, Western blot analysis 330 showed that Ro24-7429 treatment reduced the expression of RUNX1 and fibronectin whereas it 331 preserved the expression of E-Cadherin, an epithelial marker (Fig 1E-F) . Quantitative RT-PCR 332 (qRT-PCR) analysis showed up-regulation of mRNA expression for fibrosis markers including ɑ 333 -SMA, collagen 3A1, and fibronectin in lung tissue of mice instilled with bleomycin compared to 334 tissues from the saline control group (Fig. 1G) . Immunofluorescence staining and qRT-PCR 335 revealed a significant up-regulation of RUNX1 upon induction of fibrosis post bleomycin 336 instillation ( Fig. 1G-H) . This effect on RUNX1 upregulation observed in bleomycin-injured mice 337 was significantly attenuated in mice treated with Ro24-7429. Ro24-7429 treatment also blunted 338 the upregulation of fibrosis markers triggered by bleomycin compared to vehicle treated mice 339 ( Fig. 1E-H) . 340 The protective effects of the highest dose of Ro24-7429 (70 mg/kg) were further supported by 341 immunostaining analysis of ɑ-SMA, a marker of scar-forming myofibroblasts, which co-342 localized within dense fibrotic regions in the bleomycin instilled lungs but was localized only to 343 vessels (staining mural cells), as expected, in the Ro24-7429-treated mice (Fig. 1H ).

Anti-inflammatory activity of Ro24-7429 345 We evaluated the potential effect of Ro24-7429 on bleomycin-induced inflammation 1 week and 346 2 weeks after lung injury (Figs. 1I-J and 2). As expected, bleomycin did not trigger significant 347 fibrosis at the 1-week time point ( Fig. 2A-G) . As shown in Fig. 1I to that of nintedanib and pirfenidone. However, pirfenidone (500 μg/ml) caused significant cell 375 death (8%) at 48 hours, which increases to 11% at 72 hours in A549 cells (Suppl. Fig. S2D-E) . 376 We evaluated the effect of RUNX1 inhibition on the expression of fibrosis markers induced by 377 TGF-β1, a critical mediator of PF (38), in A549 cells at 24, 48 and 72 hours. We found that 378 TGF-β1 exposure strongly induced the expression of α-SMA and N-Cadherin in A549 cells using Table S1 ). Overall, these findings highlight the possibility that 412 RUNX1 might be a novel target to ameliorate lung pathology in severe COVID-19. 413 We further evaluated a potential functional link between RUNX1 function and the expression of ACE2 expression localized to the areas with increased α-SMA staining and fibrosis. Ro24-7429 419 treatment markedly reduced ACE2 staining and fibrosis in the lung (Fig. 4B) . Additionally, we 420 studied the effect of RUNX1 inhibition on the expression of ACE2 expression in TGF-β1 and 421 TNF- stimulated HPAEpi cells. We found that TGF-β1 and TNF- exposure triggered 422 upregulation of ACE2 protein levels ( Fig. 4C-D) . RUNX1 inhibition significantly reduced TGF-423 β1 and TNFα induced ACE2 protein levels in HPAEpi cells. FURIN protein levels were also 424 observed to go down by 70% in the Ro24-7429 treated mice as evaluated by Western blot (Fig.   425 4E-F). 426 We stimulated HMEC-Ls with TNF-α (5 ng/ml) to further examine the link between RUNX1 427 function and FURIN expression using qPCR analysis. Ro24-7429 significantly reduced FURIN 428 mRNA expression by 70% (Fig. 4G) whereas AI-14-91 reduced mRNA expression by 50%. Suppl. Fig. S6 ). This data supports the importance of RUNX1, as well as the JNK-AP-1-RUNX1 452 pathway (Fig. 5) , in the regulation of angiogenesis-associated genes, which are upregulated in a 453 severe COVID-19 disease state that ultimately leads to patient deaths in many cases. (46). 476 The mechanism of how SARS-CoV-2 leads to pulmonary fibrosis is yet to be determined. 477 However, it is known that viral infection is a risk factor for pulmonary fibrosis (47 A potential limitation of the study is that we cannot rule out additional effects beyond RUNX1 513 inhibition of Ro24-7429 as it has also been investigated as a Tat antagonist (30, 31) . However, to 514 validate the effects of RUNX1 inhibition in vitro we used AI-14-91 a validated RUNX1 inhibitor 515 in the HMEC-Ls. Additionally, we have shown that Ro24-7429 causes a reduction in fibrotic 516 makers, a phenotype also reported in studies that inhibited RUNX1 through molecular 517 approaches (3). We report that RUNX1 localization and signal is increased in a subset of human 518 lungs infected with SARS-CoV-2. This finding needs to be explored further in a larger sample 519 once our understanding of COVID-19 pathobiology increases. Interestingly, RUNX1 has 520 recently been predicted to modulate ACE2 and FURIN expression based on genomic-guided 521 molecular maps of upstream regulatory elements (33). We report for the first time that RUNX1 522 expression directly correlates with ACE2 and FURIN expression levels both in vitro and in vivo. 523 FURIN is a ubiquitous proprotein convertase involved in the proteolytic processing of a wide 524 range of precursor proteins and activates a number of factors that are believed to be important in 525 IPF including TGF-β1 a major contributing factor to the fibrotic changes associated with IPF. 526 Initially, TGF-β1 is produced as an inactive polypeptide that requires correct proteolytic 527 cleavage for its activation. The TGF-β1 cleavage site consists of a R-H-R-R sequence similar to In conclusion, these data indicate that RUNX1 is involved in multiple steps of the pathobiology 541 of pulmonary fibrosis and RUNX1 inhibition may lead to an effective new therapy for PF of 542 multiple etiologies. Our data suggests that RUNX1 transcriptional activity likely plays a critical 543 role in the pathologic host response to SARS-CoV-2 infection regulating the epithelial, 544 fibroblast, and endothelial cell response. Our oPOSSUM analysis of TFBSs in genes found to be 545 dysregulated in patients with COVID-19 revealed that 78% of these genes contain RUNX1 546 TFBSs suggesting that RUNX1 has an important role in the pathobiology of COVID-19 (16). 547 We surmise that repurposing of Ro24-7429 for the treatment of PF in patients with or without 548 COVID-19 should be examined in clinical trials. Ro24-7429 was tested in a phase 2 clinical trial 549 in patients with HIV. Ro24-7429 did not have sufficient antiviral activity but was found to be 550 safe at doses equal to or lower than 300 mg/day orally. A rash that appeared in a dose dependent 551 manner and recovered shortly after withdrawal was the only major side effect after 12 weeks of 552 treatment. Because Ro24-7429 was already used in immunocompromised patients it is likely to 553 be safe to test in COVID-19 patients as means to prevent or treat life-threatening complications. for his assistance and encouragement to make this work possible. human 5'-ACCCTTTCCAAATCCTCAGC-3' 5'-GTTATGGCGACCCGCAG-3' RUNX1 human 5'-TCCACAAACCCACCGCAAGT-3' 5'-CGCTCGGAAAAGGACAAGC-3' FURIN human 5'-TCGGGGACTATTACCACTTCTG-3' 5'-CCAGCCACTGTACTTGAGGC-3' ACE2 human 5'-ACAGTCCACACTTGCCCAAAT-3' 5'-TGAGAGCACTGAAGACCCATT-3' HPRT1 mouse 5'-TCAGTCAACGGGGGACATAAA-3' 5'-GGGGCTGTACTGCTTAACCAG-3' RUNX1 mouse 5'-TGGTGGAGGTACTAGCTGACC-3' 5'-CGAGTAGTTTTCATCGTTGCCTG-3' FURIN mouse 5'-AGGGACGTGTATCAGGAGCC-3' 5'-CCTGCTAGGTCGGGATGATTC-3' ACE2 mouse 5'-GGCGACAAGCACAGACTACAA-3' 5'-GCCATCTCGTTTTTCAGGACC-3' -SMA mouse 5'-GTCCCAGACATCAGGGAGTAA-3' 5'-TCGGATACTTCAGCGTCAGGA-3' TNF-R1 mouse 5'-GGGCACCTTTACGGCTTCC-3' 5'-TCTCCTTACAGGGGATTGTCAC-3' TGF1 mouse 5'-CTCCCGTGGCTTCTAGTGC-3' 5'-GCCTTAGTTTGGACAGGATCTG-3' Fibronectin mouse 5'-ATGTGGACCCCTCCTGATAGT-3' 5'-GCCCAGTGATTTCAGCAAAGG-3' Collagen mouse 5'-CTGTAACATGGAAACTGGGGAAA-3' 5'-CCATAGCTGAACTGAAAACCACC-3' 868 Table 1 : Primer sequences used in qRT-PCR analysis

Idiopathic Pulmonary Fibrosis

Idiopathic pulmonary fibrosis: an epithelial/fibroblastic cross-talk 597 disorder

LncRNA Hoxaas3 promotes 599 lung fibroblast activation and fibrosis by targeting miR-450b-5p to regulate Runx1

Impact of novel antifibrotic therapy on patient outcomes in 602 idiopathic pulmonary fibrosis: patient selection and perspectives

PROFILEing idiopathic pulmonary fibrosis: rethinking biomarker discovery

Nintedanib with Add-on Pirfenidone in 608

Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial

Global incidence and mortality of 611 idiopathic pulmonary fibrosis: a systematic review

Idiopathic Pulmonary Fibrosis in the UK

Risk Factors for Mortality after COVID-19 in Patients with 616

Preexisting Interstitial Lung Disease

Survivors: Predictive Factors and Risk Reduction Strategies

Pulmonary fibrosis and COVID-19: the potential 620 role for antifibrotic therapy

Endothelial to mesenchymal transition: a precursor to post-COVID-19 interstitial pulmonary 623 fibrosis and vascular obliteration?

Endothelial cell dysfunction: a major player in SARS-CoV-2 infection (COVID-19)? Eur Respir 626

Pathology and Pathogenesis of SARS-CoV-2 Associated with Fatal Coronavirus 630

In situ detection of SARS-CoV-2 in lungs and airways of patients with COVID-19

A systematic 638 review of pathological findings in COVID-19: a pathophysiological timeline and possible 639 mechanisms of disease progression

COVID-19 acute respiratory distress syndrome (ARDS): 641 clinical features and differences from typical pre-COVID-19 ARDS

Post covid 19 pulmonary fibrosis-Is it reversible

Remdesivir for the Treatment of Covid-19 -Final Report

Group RC. Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary 653 Report

Immunotherapy for SARS-CoV-2: potential opportunities

Yzaguirre AD, de Bruijn MFTR, Speck NA. The Role of Runx1 in Embryonic Blood 657

Cell Formation

The leukemia-associated AML1 (Runx1)-CBFβ 660 complex functions as a DNA-induced molecular clamp

Identification of benzodiazepine Ro5-3335 as an inhibitor of CBF 664 leukemia through quantitative high throughput screen against RUNX1-CBFβ interaction

Molecule Inhibitor of CBFβ-RUNX Binding for RUNX Transcription Factor Driven Cancers

TNF-α signaling regulates RUNX1 673 function in endothelial cells

Identification of RUNX1 as a Mediator of 677

Topical delivery of a small molecule RUNX1 transcription factor 682 inhibitor for the treatment of proliferative vitreoretinopathy

Inhibition of type 1 human immunodeficiency virus replication by a tat 685 antagonist to which the virus remains sensitive after prolonged exposure in vitro

A randomized trial of the activity and safety of Ro 24-7429 (Tat antagonist) versus nucleoside for human immunodeficiency virus infection. The 690 AIDS Clinical Trials Group 213 Team

Tzouvelekis 692 A, Glassberg MK. Exploring Animal Models That Resemble Idiopathic Pulmonary Fibrosis

Tripartite Combination of Candidate Pandemic Mitigation Agents: Vitamin 695

Manifest Properties of Medicinal Agents for Targeted Mitigation of 696 the COVID-19 Pandemic Defined by Genomics-Guided Tracing of SARS-CoV-2 Targets in 697 Human Cells

The effect 702 of enoxaparin on bleomycin-induced lung injury in mice

Human recombinant interferon-alpha2a and interferon-alphaA/D have different effects on 705 bleomycin-induced lung injury

Dying with SARS-CoV-2 infection-an autopsy study of the first consecutive 80 709 cases in

TGF-β: Titan of Lung Fibrogenesis

Anti-TNFα therapy in inflammatory lung diseases

Alterations in pulmonary mRNA encoding procollagens, fibronectin 715 and transforming growth factor-beta precede bleomycin-induced pulmonary fibrosis in mice

TGF-β1 regulates cell fate during epithelial-mesenchymal 718 transition by upregulating survivin

Smad3 Null Mice Develop Airspace Enlargement and Are Resistant 721 to TGF-β-Mediated Pulmonary Fibrosis

Runt-Related Transcription 723 Factor 1 (RUNX1) Promotes TGF-β-Induced Renal Tubular

Transition (EMT) and Renal Fibrosis through the PI3K Subunit p110δ

RUNX1 is essential for mesenchymal stem cell proliferation and myofibroblast 728 differentiation

Single-Cell Deconvolution of Fibroblast 731

Heterogeneity in Mouse Pulmonary Fibrosis

Viral 735 Infection Increases the Risk of Idiopathic Pulmonary Fibrosis: A Meta-Analysis

M2 macrophages promote 738 myofibroblast differentiation of LR-MSCs and are associated with pulmonary fibrogenesis

An inflammatory cytokine signature predicts COVID-19 severity and 745 survival

TNF primes endothelial cells for angiogenic sprouting by inducing a tip 748 cell phenotype

Tumor necrosis factor 750 type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo

Laskin 753 JD, Laskin DL. Attenuation of Nitrogen Mustard-Induced Pulmonary Injury and Fibrosis by 754

Necrosis Factor-α Antibody

Role of TNFα in pulmonary 756 pathophysiology

Selective tumour necrosis factor receptor-1 inhibition in acute lung 758 injury: a new hope or a false dawn? Thorax

Smads bind directly to the Jun family of AP-1 transcription factors

Feedback regulation of TGF-β signaling

Inflammatory regulatory network mediated by the joint 765 action of NF-kB, STAT3, and AP-1 factors is involved in many human cancers

Runt-Related Transcription Factor 1 Regulates LPS-Induced Acute Lung Injury 769 via NF-κB Signaling

Runx1 negatively regulates inflammatory 772 cytokine production by neutrophils in response to Toll-like receptor signaling

Furin at the cutting edge: from protein traffic to embryogenesis and disease

Evidence that 777 furin is an authentic transforming growth factor-beta1-converting enzyme

MMP28 promotes macrophage polarization toward M2 cells and augments 781 pulmonary fibrosis

N-Cadherin and ɑ-SMA at 24, 48 and 72 hours 827 treatment with TGF-β1 in A459 cells C) Quantification of Western blot for TGF-β1 time course 828 in A549 cells. D-E) Western blot showing effect of Ro24-7429 on fibrotic marker N-cadherin 829 after 72 hours treatment with TGF-β1 in A459 cells. F-G) Western blot of fibrotic marker N-830 cadherin in human alveolar epithelial cells (HPAEpi cells) stimulated with TGF-β1 or TNF-ɑ 831 with and without Ro24-7429 pretreatment. H) Representative images for HMEC-Ls 832 fluorescently labeled with CD31 (Green)

qRT-PCR analysis of mRNA levels of RUNX1 after 24, 48, and 72 hours treatment with TNF-ɑ 834 in HMEC-Ls cells. J) qRT-PCR of RUNX1 expression after pretreatment with AI

A) RUNX1 expression in 840 human control lungs and two cases with SARS-CoV-2 with low (Case 1) or high abundance of 841 viral proteins in lung (Cases 2) by immunostaining. Only Case 2 shows RUNX1 signal in 842 endothelia (yellow triangles) and capillaries (inset) (Scale Bars -100 µm). B) ACE2-ɑ-SMA 843 immunostaining at the 2-week time point (Scale -100µm). C-D) Western blot showing TGF-β1 844 and TNF-ɑ induction of ACE2